Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT with Cetuximab +/- Docetaxel in Recurrent SCCHN
NCT02057107Phase 2Completed
- Start
- Jul 2013
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel in squamous cell carcinoma of the head and neck (HNSCC) (2 arms). Primary endpoints: 1-Year Locoregional Progression-free survival, Incidence of distant disease at 1 year and 2 more. Started Jul 2013; status: completed.
02
Drugs
docetaxel
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02057107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02057107.